author_facet Blanchet, Jean-Sébastien
Brinkmann, Thomas
Blanchet, Jean-Sébastien
Brinkmann, Thomas
author Blanchet, Jean-Sébastien
Brinkmann, Thomas
spellingShingle Blanchet, Jean-Sébastien
Brinkmann, Thomas
Journal of Medical Biochemistry
The Clinical Impact of who Standardization of PSA Assays
Biochemistry (medical)
Clinical Biochemistry
author_sort blanchet, jean-sébastien
spelling Blanchet, Jean-Sébastien Brinkmann, Thomas 1452-8266 1452-8258 Centre for Evaluation in Education and Science (CEON/CEES) Biochemistry (medical) Clinical Biochemistry http://dx.doi.org/10.2478/v10011-008-0010-7 <jats:title>The Clinical Impact of who Standardization of PSA Assays</jats:title><jats:p>The determination of serum level of the prostate specific antigen (PSA) is widely used for detection and management of prostate cancer. Analytical variability between the various PSA assays on the market has been reported. This discrepancy in the PSA results was shown to be related to non-equimolar detection of total PSA (tPSA) but also to a lack of assay standardization and could have serious clinical repercussions on the diagnostic performance of PSA testing. The recalibration of equimolar assays to common reference preparations (tPSA WHO 96/670 and fPSA 96/668) was thought to promote standardization of PSA assays and limit the clinical implication of assay variability. Comparison studies have demonstrated that PSA assay calibration to the WHO standard certainly improves the harmonisation of PSA testing, but differences between assays remain. Recent evaluations of the clinical impact of analytical variations induced by a calibration to the WHO standard reported that 15% to 30% of prostate cancer could be missed if the historical tPSA cut-off was used. In order to avoid unacceptable erosion of the clinical diagnostic performance of PSA determination for the detection of prostate cancer with WHO calibrated assays, it is critical to define new specific clinical decision points.</jats:p> The Clinical Impact of who Standardization of PSA Assays Journal of Medical Biochemistry
doi_str_mv 10.2478/v10011-008-0010-7
facet_avail Online
finc_class_facet Medizin
Biologie
Chemie und Pharmazie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjQ3OC92MTAwMTEtMDA4LTAwMTAtNw
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjQ3OC92MTAwMTEtMDA4LTAwMTAtNw
institution DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
imprint Centre for Evaluation in Education and Science (CEON/CEES), 2008
imprint_str_mv Centre for Evaluation in Education and Science (CEON/CEES), 2008
issn 1452-8266
1452-8258
issn_str_mv 1452-8266
1452-8258
language Undetermined
mega_collection Centre for Evaluation in Education and Science (CEON/CEES) (CrossRef)
match_str blanchet2008theclinicalimpactofwhostandardizationofpsaassays
publishDateSort 2008
publisher Centre for Evaluation in Education and Science (CEON/CEES)
recordtype ai
record_format ai
series Journal of Medical Biochemistry
source_id 49
title The Clinical Impact of who Standardization of PSA Assays
title_unstemmed The Clinical Impact of who Standardization of PSA Assays
title_full The Clinical Impact of who Standardization of PSA Assays
title_fullStr The Clinical Impact of who Standardization of PSA Assays
title_full_unstemmed The Clinical Impact of who Standardization of PSA Assays
title_short The Clinical Impact of who Standardization of PSA Assays
title_sort the clinical impact of who standardization of psa assays
topic Biochemistry (medical)
Clinical Biochemistry
url http://dx.doi.org/10.2478/v10011-008-0010-7
publishDate 2008
physical 161-168
description <jats:title>The Clinical Impact of who Standardization of PSA Assays</jats:title><jats:p>The determination of serum level of the prostate specific antigen (PSA) is widely used for detection and management of prostate cancer. Analytical variability between the various PSA assays on the market has been reported. This discrepancy in the PSA results was shown to be related to non-equimolar detection of total PSA (tPSA) but also to a lack of assay standardization and could have serious clinical repercussions on the diagnostic performance of PSA testing. The recalibration of equimolar assays to common reference preparations (tPSA WHO 96/670 and fPSA 96/668) was thought to promote standardization of PSA assays and limit the clinical implication of assay variability. Comparison studies have demonstrated that PSA assay calibration to the WHO standard certainly improves the harmonisation of PSA testing, but differences between assays remain. Recent evaluations of the clinical impact of analytical variations induced by a calibration to the WHO standard reported that 15% to 30% of prostate cancer could be missed if the historical tPSA cut-off was used. In order to avoid unacceptable erosion of the clinical diagnostic performance of PSA determination for the detection of prostate cancer with WHO calibrated assays, it is critical to define new specific clinical decision points.</jats:p>
container_issue 2
container_start_page 161
container_title Journal of Medical Biochemistry
container_volume 27
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792339628313804810
geogr_code not assigned
last_indexed 2024-03-01T15:49:51.657Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+Clinical+Impact+of+who+Standardization+of+PSA+Assays&rft.date=2008-01-01&genre=article&issn=1452-8258&volume=27&issue=2&spage=161&epage=168&pages=161-168&jtitle=Journal+of+Medical+Biochemistry&atitle=The+Clinical+Impact+of+who+Standardization+of+PSA+Assays&aulast=Brinkmann&aufirst=Thomas&rft_id=info%3Adoi%2F10.2478%2Fv10011-008-0010-7&rft.language%5B0%5D=und
SOLR
_version_ 1792339628313804810
author Blanchet, Jean-Sébastien, Brinkmann, Thomas
author_facet Blanchet, Jean-Sébastien, Brinkmann, Thomas, Blanchet, Jean-Sébastien, Brinkmann, Thomas
author_sort blanchet, jean-sébastien
container_issue 2
container_start_page 161
container_title Journal of Medical Biochemistry
container_volume 27
description <jats:title>The Clinical Impact of who Standardization of PSA Assays</jats:title><jats:p>The determination of serum level of the prostate specific antigen (PSA) is widely used for detection and management of prostate cancer. Analytical variability between the various PSA assays on the market has been reported. This discrepancy in the PSA results was shown to be related to non-equimolar detection of total PSA (tPSA) but also to a lack of assay standardization and could have serious clinical repercussions on the diagnostic performance of PSA testing. The recalibration of equimolar assays to common reference preparations (tPSA WHO 96/670 and fPSA 96/668) was thought to promote standardization of PSA assays and limit the clinical implication of assay variability. Comparison studies have demonstrated that PSA assay calibration to the WHO standard certainly improves the harmonisation of PSA testing, but differences between assays remain. Recent evaluations of the clinical impact of analytical variations induced by a calibration to the WHO standard reported that 15% to 30% of prostate cancer could be missed if the historical tPSA cut-off was used. In order to avoid unacceptable erosion of the clinical diagnostic performance of PSA determination for the detection of prostate cancer with WHO calibrated assays, it is critical to define new specific clinical decision points.</jats:p>
doi_str_mv 10.2478/v10011-008-0010-7
facet_avail Online
finc_class_facet Medizin, Biologie, Chemie und Pharmazie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMjQ3OC92MTAwMTEtMDA4LTAwMTAtNw
imprint Centre for Evaluation in Education and Science (CEON/CEES), 2008
imprint_str_mv Centre for Evaluation in Education and Science (CEON/CEES), 2008
institution DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14
issn 1452-8266, 1452-8258
issn_str_mv 1452-8266, 1452-8258
language Undetermined
last_indexed 2024-03-01T15:49:51.657Z
match_str blanchet2008theclinicalimpactofwhostandardizationofpsaassays
mega_collection Centre for Evaluation in Education and Science (CEON/CEES) (CrossRef)
physical 161-168
publishDate 2008
publishDateSort 2008
publisher Centre for Evaluation in Education and Science (CEON/CEES)
record_format ai
recordtype ai
series Journal of Medical Biochemistry
source_id 49
spelling Blanchet, Jean-Sébastien Brinkmann, Thomas 1452-8266 1452-8258 Centre for Evaluation in Education and Science (CEON/CEES) Biochemistry (medical) Clinical Biochemistry http://dx.doi.org/10.2478/v10011-008-0010-7 <jats:title>The Clinical Impact of who Standardization of PSA Assays</jats:title><jats:p>The determination of serum level of the prostate specific antigen (PSA) is widely used for detection and management of prostate cancer. Analytical variability between the various PSA assays on the market has been reported. This discrepancy in the PSA results was shown to be related to non-equimolar detection of total PSA (tPSA) but also to a lack of assay standardization and could have serious clinical repercussions on the diagnostic performance of PSA testing. The recalibration of equimolar assays to common reference preparations (tPSA WHO 96/670 and fPSA 96/668) was thought to promote standardization of PSA assays and limit the clinical implication of assay variability. Comparison studies have demonstrated that PSA assay calibration to the WHO standard certainly improves the harmonisation of PSA testing, but differences between assays remain. Recent evaluations of the clinical impact of analytical variations induced by a calibration to the WHO standard reported that 15% to 30% of prostate cancer could be missed if the historical tPSA cut-off was used. In order to avoid unacceptable erosion of the clinical diagnostic performance of PSA determination for the detection of prostate cancer with WHO calibrated assays, it is critical to define new specific clinical decision points.</jats:p> The Clinical Impact of who Standardization of PSA Assays Journal of Medical Biochemistry
spellingShingle Blanchet, Jean-Sébastien, Brinkmann, Thomas, Journal of Medical Biochemistry, The Clinical Impact of who Standardization of PSA Assays, Biochemistry (medical), Clinical Biochemistry
title The Clinical Impact of who Standardization of PSA Assays
title_full The Clinical Impact of who Standardization of PSA Assays
title_fullStr The Clinical Impact of who Standardization of PSA Assays
title_full_unstemmed The Clinical Impact of who Standardization of PSA Assays
title_short The Clinical Impact of who Standardization of PSA Assays
title_sort the clinical impact of who standardization of psa assays
title_unstemmed The Clinical Impact of who Standardization of PSA Assays
topic Biochemistry (medical), Clinical Biochemistry
url http://dx.doi.org/10.2478/v10011-008-0010-7